Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Padcev
Pharma
FDA expands Padcev-Keytruda combo to more MIBC patients
Padcev and Keytruda have become the first muscle-invasive bladder cancer treatment that covers patients regardless of cisplatin eligibility.
Angus Liu
Jul 10, 2026 1:10pm
Inside Astellas CEO's plan to counter Xtandi's patent cliff
Jun 11, 2026 6:00pm
AZ’s Imfinzi gains ground on Keytruda in bladder cancer race
May 14, 2026 11:52am
Pfizer's COVID franchise keeps guidance level after strong Q1
May 5, 2026 11:17am
Astellas projects Xtandi decline but overall growth in FY2026
Apr 27, 2026 11:30am
Kyowa, Sino Biopharm, Duality—Fierce Pharma Asia
Mar 6, 2026 9:35am
